/Investor DB

Prime Movers — Full Portfolio

5 tracked investments · listed companies and verified rows first

Paradromicsparadromics.comin𝕏Apr 2023SEC filingmedium confidence

Paradromics develops a brain-computer interface (BCI) system, with FDA Breakthrough Device Designations for speech decoding and digital device control, and works with academic medical institutions on translational BCI research.

BiotechDeep TechHealthtechMedical DevicesAustin, US

Matt Angle(Founder and CEO)inRon Kelly(Director)Thomas Krummel(Director)Adam Kablanian(Director)

Board seatDakin Sloss· per SEC Form D · $34.6M raise · filed Apr 2023

Co-investors15th RockAlpha EdisonAnthropy PartnersATEL VenturesCapital FactoryCloudStone Capital+27 more

Prorata Aiprorata.aiin𝕏Sep 2024SEC filingmedium confidence

ProRata builds attribution and revenue-sharing solutions for AI search, tracking how licensed content is used and sharing revenue with content creators and publishers.

AI & Machine LearningCreator EconomyMedia & EntertainmentPasadena, US

Bill Gross(Founder & CEO)inMarcia Goodstein(Executive Officer)inSusan Aledort(Executive Officer)Nagraj Kashyap(Director)inNicholas Thompson(Director)

Board seatDakin Sloss· per SEC Form D · $4.8M raise · filed Sep 2024

Co-investorsAlumni VenturesBold Capital PartnersCalibrate VenturesFirestreak VenturesLink VenturesMVP Ventures+4 more

NobleAInoble.aiinMar 2019

NobleAI develops a science-based AI platform that uses machine learning to accelerate product innovation and discovery for chemical and materials companies.

Advanced ManufacturingAI & Machine LearningCloud ComputingData & InfrastructureDeep TechEnergyNew Materials

Alex Wang(Chief Executive Officer)in

Co-investorsM12 (Microsoft's Venture Fund)Chevron Technology VenturesPrime Movers LabTouring CapitalAlumni VenturesBaruch Future Ventures+4 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

C19Vaxxinity, Inc.

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.